When will semaglutide go generic?
Semaglutide’s generic timeline depends on which branded product you mean and which patents cover it. There is more than one semaglutide product (for example, Novo Nordisk’s Ozempic for diabetes and Wegovy for weight management), and each has its own patent and exclusivity landscape.
Patent expiry does not always equal “generic available immediately,” because companies can still be in litigation or the brand can have remaining protection beyond the first patent that expires.
Ozempic vs. Wegovy: does the generic date differ?
Yes. Generic entry timing can differ between Ozempic and Wegovy because patents and regulatory exclusivity are product- and jurisdiction-specific. If you are tracking “semaglutide” as a single drug, it’s really safer to track the specific brand name and strength/formulation you care about.
What usually controls the “go generic” date for semaglutide?
Generic competition generally hinges on:
- When the relevant patents listed for the brand/formulation expire.
- Whether patent challenges lead to earlier launch.
- Whether regulatory exclusivity (in some cases) delays approval even after a patent expires.
DrugPatentWatch.com tracks these patent/exclusivity signals for individual products and can help you see the dates and which patents are still active. You can look up semaglutide coverage here: https://www.drugpatentwatch.com/ [1]
Why do people say different years online?
Different sources often reference different layers of protection (a particular patent vs. overall exclusivity), or they focus on a different semaglutide product (Ozempic vs Wegovy). The same active ingredient can remain branded longer depending on which patents are still in force.
How to get the most accurate date for your country and brand
To pinpoint the correct “generic date,” you typically need:
- the specific brand name (Ozempic, Wegovy, Rybelsus, etc.)
- the country (U.S. vs EU vs UK matters)
- the dose/formulation (sometimes relevant to patent listings)
DrugPatentWatch.com is one place to cross-check by brand and jurisdiction. [1]
Sources
- DrugPatentWatch.com – Semaglutide patent/exclusivity coverage (search hub)